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Korean Guidelines for the Prevention of Venous 
Thromboembolism
This guideline focuses on the primary prevention of venous thromboembolism (VTE) in 
Korea. The guidelines should be individualized and aim at patients scheduled for major 
surgery, as well as patients with a history of trauma, high-risk pregnancy, cancer, or other 
severe medical illnesses. Currently, no nation-wide data on the incidence of VTE exist, and 
randomized controlled trials aiming at the prevention of VTE in Korea have yielded few 
results. Therefore, these guidelines were based on the second edition of the Japanese 
Guidelines for the Prevention of VTE and the eighth edition of the American College of 
Chest Physicians (ACCP) Evidenced-Based Clinical Practice Guidelines. These guidelines 
establish low-, moderate-, and high-risk groups, and recommend appropriate 
thromboprophylaxis for each group.
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INTRODUCTION
Venous thromboembolism (VTE) is a thrombotic disorder of 
the venous system, which includes deep vein thrombosis (DVT) 
and pulmonary embolism (PE). Approximately half of all un-
treated DVT cases are complicated by PE, and conversely, 50% 
to 80% of all untreated PE cases are associated with DVT (1, 2).
  VTE is a well-recognized, public health issue in developed 
countries. In the United States of America, 200,000 new cases of 
PE occur each year, and 50,000 of these result in death. PE is the 
third most common fatal vascular disorder following coronary 
artery disease (CAD) and cerebrovascular accident (CVA) (3). 
Thromboprophylaxis has been recommended for the following 
reasons: the high incidence of VTE in hospitalized patients; the 
difficulty of early diagnosis due to vague symptomatology; the 
cost-effectiveness of medical prophylaxis; and, the high mortal-
ity of PE without early diagnosis and adequate treatment. Health 
authorities in developed countries have established guidelines 
based on the available evidence and recommended thrombo-
prophylaxis to medical societies in order to improve health stan-
dards and reduce health costs (4, 5).
  The incidence of VTE in the Korean population has known to 
be lower than in the Caucasian population; however, it appears 
to be rapidly increasing in large part from the widespread adop-
tion of the Western lifestyle. Additionally, the elderly comprise 
the largest proportion of the Korean population, and advanced 
age has been recognized as a risk factor for VTE. Despite the rise 
in the incidence of VTE, many physicians in Korea still are not 
aware of the significance of VTE and the risk of sudden death 
associated with inappropriate management of this condition. 
Recently, we published a guidline which was a revised version 
of the Japanese Guidelines for the Prevention of VTE; however, 
it was cumbersome for physicians to read (6). The following 
guidelines represent a simplified, practical version of the afore-
mentioned guidelines, complete with risk stratification (low, 
moderate, and high) and thromboprophylaxis recommenda-Bang S-M, et al.  •  Korean Guidelines for the Prevention of VTE
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tions for each group.
GENERAL GUIDELINES
Risk stratification
Accurate and prompt stratification of thrombotic risk should be 
undertaken for every patient based on available evidence. The 
method for risk evaluation should be simple, efficient, and cost-
effective. Most hospitalized patients have at least one risk factor 
for VTE, and decisions regarding the risk of VTE should include 
considerations of current and future risks (7). Accepted risk fac-
tors for the development of VTE include previous VTE; major 
surgery; pelvis or femur fracture; major trauma; cancer; preg-
nancy and the postpartum period; long-term immobilization; 
comorbidities such as congestive heart failure (CHF), chronic 
obstructive pulmonary disease (COPD) requiring mechanical 
ventilation, or CVA; spinal cord injury (SCI), old age, obesity, 
estrogen replacement therapy, varicose veins, and other acquired 
or hereditary thrombophilic conditions.
  Selection of the appropriate thromboprophylaxis depends 
upon the level of thrombotic risk taken on by each patient (8-
10). The general consensus establishes obesity, exogenous es-
trogen, and varicose veins as low-risk conditions; advanced age, 
prolonged immobilization, CHF, COPD, central venous catheter 
placement, chemotherapy, and sepsis as moderate-risk condi-
tions; and, previous VTE, hereditary thrombophilia, and lower 
extremity paralysis as high-risk conditions.
  The American College of Chest Physicians (ACCP) Evidenced-
Based Clinical Practice Guidelines (8th Edition) for the Preven-
tion of VTE uses three thrombotic risk groups (low, moderate, 
and high) based on clinical evidence in the Caucasian popula-
tion. Thromboprophylaxis is recommended for all patients with 
a moderate or high risk for VTE (11). However, the Japanese 
Guideline recommends that active prophylaxis should be initi-
ated at one level higher than the ACCP guidelines because the 
Japanese population is less susceptible to VTE than the Cauca-
sian population. The Korean Society on Thrombosis and He-
mostasis (KSTH) adopted the Japanese risk stratification guide-
lines due to the ethnic similarity between the Korean and Japa-
nese populations.
Thromboprophylaxis
Screening compression ultrasonography (CUS) or pulmonary 
computed tomography (CT) angiography can be used to detect 
VTE in some patients, like only in high-risk patients who can 
not receive thrombophylaxis; however, these modalities are ex-
pensive and unreliable at times. These are not routinely recom-
mended for detection of VTE instead of pharmacoprophylaxsis. 
Non-pharmacologic methods are applicable in patients with a 
high bleeding risk. However, supportive evidence is limited, and 
they are not cost-effective. Pharmacologic methods are reason-
able and cost-effective, and are therefore recommended as the 
initial form of prophylaxis in most patients without a high bleed-
ing risk.
 
Non-pharmacologic methods
Exercise increases venous blood flow and reduces venous sta-
sis, and thus, helps prevent VTE. However, no standardized ex-
ercise has been implemented for the prevention of VTE in hos-
pitalized patients. The application of graduated compression 
stockings (GCS) at the time of admission can prevent VTE in at-
risk patients. Use of intermittent pneumatic compression (IPC) 
can be helpful in at-risk surgical patients (Table 1) (12). Place-
ment of an inferior vena cava (IVC) filter is only recommended 
for patients at high-risk of VTE when pharmacologic thrombo-
prophylaxis is contraindicated (13-16).
Pharmacologic methods
Pharmacologic methods for thromboprophylaxis include low-
molecular weight heparin (LMWH), low-dose unfractionated 
heparin (LDUH), fondaparinux, warfarin, dabigatran, and riva-
roxaban. The recommended daily doses are LMWH 20-100 U/
kg (0.2-1 mg/kg) subcutaneously (SC) daily; LDUH 5,000 U ev-
ery 8 to 12 hr SC, fondaparinux 2.5 mg SC daily; dabigatran etex-
ilate 150 mg every 12 hr orally; and, rivaroxaban 10 mg orally 
each day. Warfarin should be dosed daily to maintain an inter-
national normalized ratio (INR) in the range 1.5 to 2.5 (Table 1). 
The duration of thromboprophylaxis depends upon the per-
ceived benefits of anticoagulation versus the risks of bleeding 
and overall cost.
Stratification of VTE risk in hospitalized patients
Based on clinical evidence, the risk of VTE in surgical patients 
can be stratified from low to high (Table 2). High-risk situations 
include major surgery in patients with previous VTE or a hyper-
coagulable state, major orthopedic surgery, CVA, major trauma, 
or SCI. 
  The Korean guidelines are not based upon clinical evidence, 
Table 1. Methods of thromboprophylaxis
Methods Prescription or dosage and route 
Mechanical prophylaxis
   Graduated compression stocking (GCS) 
   Intermittent pneumatic compression (IPC)
Pressure of stocking with 
16-20 mmHg 
Repeat inflation (11-12 sec)  
and deflation (60 sec)
Pharmacologic prophylaxis
   LMWH
   LDUH
   Warfarin 
   Fondaparinux
   Rivaroxaban
   Dabigatran etexilate 
0.2-1 mg/kg SC daily
5,000 U SC every 8-12 hr 
Dose adjust for PT (INR) with 1.5-2.5 
2.5 mg SC daily 
10 mg PO daily 
150 mg PO every 12 hr 
LMWH, low-molecular-weight heparin; LDUH, low-dose unfractionated heparin; SC, 
subcutaneously; PT, prothrombin time; INR, international normalized ratio; PO, per os. Bang S-M, et al.  •  Korean Guidelines for the Prevention of VTE
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but rather upon a consensus in experts panel of Korean Society 
of Thrombosis and Hemostasis (KSTH). Therefore, these guide-
lines represent the most current opinions for good clinical prac-
tices for the prevention of VTE. The ultimate decision regarding 
thromboprophylaxis should be individualized by case and de-
termined by the attending physician.
GENERAL SURGERY
The principles of risk assessment for general surgery are based 
on the type of surgery (minor or major), age (<40 yr, 40-60 yr, 
and ≥60 yr), and the presence of additional risk factors, such as 
cancer or previous VTE (11). According to these principles, cas-
es were classified into three risk groups (Table 3). Early and fre-
quent ambulation was recommended for low-risk patients. 
Mechanical methods (GCS and/or IPC) or pharmacologic meth-
ods (LMWH, LDUH, or fondaparinux) are recommended for 
moderate-risk patients. LMWH, fondaparinux, or warfarin are 
recommended for high-risk patients scheduled for major can-
cer surgery with additional risk factors for VTE and for high-risk 
patients with a previous VTE or thrombophilia. When antico-
agulation is contraindicated in a high-risk patient, IPC is rec-
ommended. For patients undergoing entirely laparoscopic pro-
cedures who do not have additional thromboembolic risk fac-
tors, routine use of thromboprophylaxis (other than early and 
frequent ambulation) is discouraged (17).
ORTHOPEDIC SURGERY
Patients scheduled for major orthopedic surgery, including to-
tal hip replacement (THR), total knee replacement (TKR), and 
hip fracture surgery (HFS), represent a group at particularly 
high risk of VTE. In the West, the incidence of VTE among pa-
tients that undergo major orthopedic surgery ranges from 41% 
to 60%, but the epidemiological data on the incidence of VTE in 
the Asian population varies (11). A recent Korean study found 
the incidence of postoperative VTE in TKR, THR, and HFS, to 
be 40.4%, 8.7%, and 16.4%, respectively, using CT pulmonary 
angiography and indirect CT venography (18).
  For patients scheduled to undergo TKR, THR, or HFS, LMWH, 
warfarin or fondaparinux is recommended for thrombopro-
phylaxis (Table 4) (19, 20). GCS and/or IPC are recommended 
in patients with a risk of bleeding. The current recommended 
duration for anticoagulation is 7 to 10 days, but extended use 
through 35 days has been proposed in the 8th ACCP guideline 
for the prevention of VTE after discharge from the hospital (4).
  Patients scheduled for vertebral surgery have a moderate risk 
for VTE and should wear GCS and/or utilize IPC. Patients sched-
uled for surgery of the upper extremity or lower leg (distal to the 
knee) has a low risk for VTE and do not require prophylaxis. Rou-
tine CUS screening is not helpful in these patients.
NEUROSURGERY
The incidence of DVT and subsequent PE in neurosurgery pa-
tients has been reported as high as 25%, and the PE mortality 
rate has been reported from 9% to 50% (21, 22). The risk factors 
that contribute to the high frequency of VTE in neurosurgical 
patients include a prior VTE; type of surgery (cranial, spinal, or 
vascular); duration of surgery; malignancy; infection; immobi-
lization; venous stasis; chronic lower extremity swelling; lower 
Table 2. VTE risk-stratification and recommended prophylactic methods for each risk 
group
Risk  Patients or Surgery Thromboprophylaxis
Low Minor surgery in mobile patients,  
Medical patients who are fully mobile
Not necessary and
Early ambulation
Moderate General open gynecological surgery, 
General open urologic surgery,  
Medical patients on bed rest or sick
GCS, IPC, LMWH, LDUH 
or Fondaparinux
High THR, TKR, HFS, Major trauma, 
Spinal cord injury, Major surgery  
in patients with previous VTE  
or thrombophilia 
LMWH, Warfarin or
Fondaparinux; IPC*
*Recommended for patients with a risk of bleeding; consider switching to anticoa-
gulants when the bleeding risk abates. 
VTE, venous thromboembolism; GCS, graduated compression stockings; IPC, inter-
mittent pneumatic compression; LMWH, low-molecular-weight heparin; LDUH, low-
dose unfractionated heparin; THR, total hip replacement; TKR, total knee replacement; 
HFS, hip fracture surgery.
Table 3. Levels of VTE risk and recommendations for general surgery
Risk group Procedures Thromboprophylaxis 
Low  Major surgery in age <40 yr, 
Minor surgery in age <60 yr
Early ambulation
Moderate  Major surgery in age >40 yr  
or with risk factor, 
Non-major surgery in age >60 yr  
or with risk factor
GCS, IPC, LMWH, LDUH,  
or Fondaparinux
High Major cancer surgery with additional risk 
factor, Major surgery in patients with 
previous VTE or thrombophilia
LMWH, Warfarin, or 
Fondaparinux; IPC*
*Recommended in patients with a risk of bleeding; consider switching to anticoagulants 
when the bleeding risk abates. 
VTE, venous thromboembolism; GCS, graduated compression stockings; IPC, inter-
mittent pneumatic compression; LMWH, low-molecular-weight heparin; LDUH, low-
dose unfractionated heparin; VTE, venous thromboembolism.
Table 4. Levels of VTE risk and recommendations for orthopedic surgery
Risk group Procedures Thromboprophylaxis 
Low  Surgery of upper extremity,  
Surgery of fracture distal to the knee
Early ambulation
Moderate  Vertebral surgery GCS or IPC
High Total hip replacement, Total knee 
replacement, Hip fracture surgery
LMWH, Warfarin, or 
Fondaparinux; IPC*
*Recommended in patients with a risk of bleeding; consider switching to anticoagulants 
when the bleeding risk abates. 
VTE, venous thromboembolism; GCS, graduated compression stockings; IPC, inter-
mittent pneumatic compression; LMWH, low-molecular-weight heparin; LDUH, low-
dose unfractionated heparin.Bang S-M, et al.  •  Korean Guidelines for the Prevention of VTE
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extremity trauma; advanced age; CHF; obesity; and, sleep apnea.
  Early and frequent ambulation for low-risk neurosurgery pa-
tients who have undergone surgery (not craniotomy) is recom-
mended. For moderate-risk patients scheduled for craniotomy 
(for reasons other than brain tumor), GCS and/or IPC is recom-
mended. IPC, LDUH or LMWH are suggested for patients sched-
uled for craniotomy for a brain tumor. For high-risk patients 
scheduled for craniotomy with a concomitant history of VTE or 
thrombophilia, a combined thromboprophylactic approach with 
a mechanical method (GCS and/or IPC) and a pharmacologic 
method (LMWH or LDUH) is recommended.
UROLOGIC SURGERY
Risk factors for VTE in urologic surgery patients include an age 
≥40 yr, obesity, malignancy, recent surgery, previous VTE, an 
open (vs transurethral) procedure, general anesthesia, and a 
long operation time. Major urologic surgery may present higher 
risks of PE and VTE than general surgery. 
  The risk of VTE has been associated with operation time (<45 
min and ≥45 min). For patients scheduled for a low-risk proce-
dure, early ambulation and exercise without any other form of 
thromboprophylaxis is recommended. On the other hand, for 
patients scheduled for major surgery, thromboprophylaxis with 
GCS or IPC; LMWH, LDUH, or fondaparinux; or a combination 
of mechanical and pharmacologic thromboprophylaxis is indi-
cated. For abdominal (open) surgery on the kidney or retroper-
itoneum, the aforementioned principles outlined for general 
surgery should be followed. Nephrectomy presents the same 
level of risk as radical prostatectomy.
 
OBSTETRIC AND GYNECOLOGIC SURGERY
The incidence of VTE is high in pregnancy and may occur at any 
stage during pregnancy or in the weeks following delivery. The 
risk factors for VTE in pregnant women include previous VTE, 
a family history of VTE, presence of anti-phospholipid antibody, 
age ≥40 yr, prolonged bed rest, placenta previa, Caesarian sec-
tion, and lower extremities varicosities. For women with a his-
tory of abortion, intrauterine death, toxemia, placenta previa, 
and intrauterine growth retardation, monitoring for thrombo-
philia and evaluating for thrombosis must be continued through-
out the pregnancy.
  Giant uterine myoma, previous surgery for an ovarian tumor, 
ovarian cancer, uterine or cervical cancer, severe intrapelvic ad-
hesions, ovarian hyperstimulation syndrome, hormonal thera-
py, and particularly, protracted lymph node dissection requir-
ing transfusion are considered important risk factors for VTE 
(23, 24). Estrogen or progesterone should be administered with 
caution in postmenopausal women with a high risk of VTE.
  For patients with risk factors, general thromboprophylaxis, 
such as, lower extremity exercise on a bed, GCS, IPC, and ade-
quate hydration postpartum are recommended. Early ambula-
tion should be encouraged even after a normal delivery in low-
risk patients. In addition, pharmacologic thromboprophylaxis 
with LMWH or warfarin should be considered in patients with 
risk factors other than Caesarian section. For high-risk pregnan-
cies with documented thrombophilia, such as, positive anti-phos-
pholipid antibody or previous VTE, pharmacologic thrombopro-
phylaxis with LMWH is recommended (25). Warfarin is contra-
indicated during pregnancy (category X) (26). However, warfa-
rin can replace LMWH after delivery and be used for 6 weeks to 
3 months for continued postpartum thromboprophylaxis (25). 
For patients with gynecologic disease, management strategies 
should follow those outlined for general surgery patients.
MEDICAL CONDITIONS
Acutely ill medical patients represent a clinically heterogeneous 
group and demonstrate differing risks of VTE. Despite extensive 
studies in medical patients, the morbidity and mortality of VTE 
remains significant. Without prophylaxis, the incidence of DVT 
and PE in general medical patients has been reported to range 
from 10% to 30% (5, 27, 28).
  The risk of VTE was determined by assessing the probability 
of VTE in acutely ill medical patients according to predisposing 
risk factors (age >70 yr, obesity, long-term immobility, tobacco 
use, varicosities, dehydration, estrogens, cancer, previous DVT, 
paraplegia, congenital or acquired thrombophilia, and inflam-
matory bowel disease [IBD]) and acute medical illnesses cur-
rently under treatment (COPD exacerbation, mechanical venti-
lator therapy, infection, CHF, and CVA) (Table 5). Acute ischemic 
Table 5. Risk factors of VTE in general medical patients
Baseline risk factors Acute medical illness
Low Obesity, Smoking, Varicose vein, Dehydration, HRT, OCs  Acute exacerbation of COPD without mechanical ventilation
Intermediate Old age (>70 yr), Long term immobilization, Active cancer, Pregnancy, 
Central venous catheterization, Nephrotic syndrome,  
Inflammatory bowel disease
Infection associated with immobility, Acute exacerbation of COPD with 
mechanical ventilation, Sepsis, MI, CHF (NYHA grade III or IV)
High Past history of VTE, Thrombophilia*, Paraplegia Cerebral stroke complicated with paralysis
*congenital thrombophilia such as antithrombin III deficiency or protein C or S deficiency, or acquired thrombophilia like antiphospholipid antibody syndrome. 
VTE, venous thromboembolism; HRT, hormone replacement therapy; OCs, oral contraceptives; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; CHF, 
congestive heart failure; NYHA, New York Heart Association, VTE, venous thromboembolism.Bang S-M, et al.  •  Korean Guidelines for the Prevention of VTE
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stroke patients with restricted mobility should have LDUH or 
LMWH administrated 24 hr after thrombolytic therapy. If a pa-
tient has an acute intracranial hemorrhage or a contraindica-
tion to anticoagulation, GCS and/or IPC can be used. However, 
GCS and IPC can increase venous return and should be used 
carefully in cases of fluid overload, such as severe CHF. For am-
bulatory cancer patients with cyclic chemotherapy, routine 
thromboprophylaxis is not recommended; however, cancer pa-
tients with restricted mobility due to other acute medical illness-
es are considered high-risk and should have thromboprophy-
laxis administered (4).
  Patients with CHF, COPD, sepsis, or IBD also have a higher 
prevalence of VTE, and thromboprophylaxis using GCS, IPC, 
LMWH, LDUH, or fondaparinux is recommended (29, 30). The 
majority of patients admitted to the intensive care unit (ICU) 
have multiple risk factors for VTE. These patients should be rou-
tinely assessed and offered thromboprophylaxis with LDUH or 
LMWH. GCS and/or IPC can be used when there is a contrain-
dication to anticoagulation.
MAJOR TRAUMA AND SPINAL CORD INJURY
Patients with major trauma are classified as high-risk. Major 
trauma includes multiple serious injuries, head trauma with 
mental status changes, severe pelvic fracture, and multiple frac-
tures of a lower extremity. VTE can cause significant morbidity 
in patients experiencing major trauma and occurs in up to 50% 
of patients without thromboprophylaxis (31). Furthermore, PE 
represents the third-leading cause of death among those who 
survive beyond 24 hr. 
  Routine thromboprophylaxis is recommended for all major 
trauma patients. Those patients with a high bleeding risk should 
receive LMWH or LDUH after primary hemostasis. On the other 
hand, if pharmacologic thromboprophylaxis is contraindicated 
due to active bleeding or a sustained high risk of bleeding, me-
chanical (GCS or IPC) thromboprophylaxis should be imple-
mented.
  All patients with acute SCI should receive routine thrombo-
prophylaxis. Initially, GCS and/or IPC and careful observation 
for bleeding is recommended, followed by LMWH thrombo-
prophylaxis when primary hemostasis is complete. For patients 
with a high bleeding risk, such as those with intra-abdominal 
bleeding, traumatic subarachnoid hemorrhage, or spinal hema-
toma, pharmacologic thromboprophylaxis should be delayed 
until the risk of further bleeding has diminished.
NEURAXIAL ANESTHESIA
Neuraxial anesthesia is a comprehensive term used for spinal, 
epidural, and caudal blocks. The risk for the development of 
spinal or epidural hematoma may be elevated by the concomi-
tant use of anticoagulants and antiplatelet agents (32, 33). The 
established risk factors for spinal or epidural hematoma after 
neuraxial blockade include an underlying hemostatic disorder, 
an anatomically-deformed vertebral column, traumatic inser-
tion of a needle or catheter, repeated insertion attempts, con-
comitant anticoagulation, continuous use of epidural catheters, 
and old age (11, 34).
  To improve the safety of neuraxial blockade in patients receiv-
ing or scheduled to receive anticoagulant prophylaxis, several 
guidelines have been established. Neuraxial anesthesia/anal-
gesia should generally be avoided in patients with a bleeding 
disorder and in situations when preoperative hemostasis is im-
paired by antithrombotic drugs. An epidural catheter should be 
removed when the anticoagulant effect is minimal (usually just 
before the next scheduled SC injection). Anticoagulation pro-
phylaxis should be delayed for at least 2 hr after the removal of 
a spinal needle or epidural catheter. If warfarin is required, con-
tinuous epidural analgesia should not be used for longer than 1 
or 2 days. Finally, monitoring for cord compression syndrome 
is required when patients are receiving anticoagulation medi-
cation (32, 35).
SUMMARY
These guidelines emphasize the primary prevention of VTE with 
thromboprophylaxis for Korean patients experiencing surgery, 
obstetric delivery, trauma, cancer, and severe medical illness. 
Based on VTE risk factors (age, immobility, history of VTE, co-
morbid illness, and type of surgery or trauma), patients can be 
stratified into low-, moderate-, and high-risk groups. For high-
risk patients (major orthopedic surgery, major trauma, SCI, and 
major surgery with a history of VTE or thrombophilia), throm-
boprophylaxis with LMWH, warfarin, or fondaparinux is recom-
mended. Mechanical methods of thromboprophylaxis should 
be used primarily in patients with a high bleeding risk. For mod-
erate-risk patients (general open gynecological surgery, general 
open urologic surgery, and medical patients on bed rest), throm-
boprophylaxis with either a mechanical method (GCS and/or 
IPC) or a pharmacologic method (LMWH, LDUH, or fondapa-
rinux) can be utilized. For low-risk patients (minor surgery in 
mobile patients and medical patients who are fully mobile), 
early and frequent ambulation is the only recommended throm-
boprophylaxis. In conclusion, this article outlines the first Kore-
an guidelines issued for primary VTE prevention and provides 
a useful reference for clinicians. These guidelines need to be 
updated based on results from well controlled studies conduct-
ed in Korea.
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